Following intratumoral administration of cholesterol-conjugated si-PAFAH1B3, a significant reduction in tumor growth and tumor weight was observed compared to the PBS and NC groups (Figure 7a–c). This evidence concerns the gene PAFAH1B3 and neoplasm.